Original article

Effect of methylprednisolone therapy on hospital stay and viral clearance in patients with moderate COVID-19

Xiaoyan Li, Xin Yuan, Zhe Xu, Lei Huang, Lei Shi, Xuechun Lu, Fu-Sheng Wang, Junliang Fu

A R T I C L E   I N F O

Keywords:
COVID-19
Hospital stay
In-hospital death
Moderate
Viral clearance

A B S T R A C T

Background: The benefits and harms of methylprednisolone treatment in patients with moderate coronavirus disease 2019 (COVID-19) remain controversial. In this study, we investigated the effect of methylprednisolone on mortality rate, viral clearance, and hospitalization stay in patients with moderate COVID-19.

Methods: This retrospective study included 4827 patients admitted to Wuhan Huoshenshan and Wuhan Guanggu hospitals from February to March 2020 diagnosed with COVID-19 pneumonia. The participants’ epidemiological and demographic data, comorbidities, laboratory test results, treatments, outcomes, and vital clinical time points were extracted from electronic medical records. The primary outcome was in-hospital death; secondary outcomes were time from admission to viral clearance and hospital stay. Univariate and multivariate logistic or linear regression analysis were used to assess the roles of methylprednisolone in different outcomes. The propensity score matching (PSM) method was used to control for confounding factors.

Results: A total of 1320 patients were included in this study, of whom 100 received methylprednisolone. Overall, in-hospital mortality was 0.91% (12/1320); the 12 patients who died were all in the methylprednisolone group, though multivariate logistic regression analysis showed methylprednisolone treatment was not a risk factor for in-hospital death in moderate patients before or after adjustment for confounders by PSM. Methylprednisolone treatment was correlated with longer length from admission to viral clearance time and hospital stay before and after adjustment for confounders.

Conclusions: Methylprednisolone therapy was not associated with increased in-hospital mortality but with delayed viral clearance and extended hospital stay in moderate COVID-19 patients.

1. Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2), has developed into a pandemic since 2019. As of July 11, 2022, there have been 551,226,298 confirmed cases of COVID-19 and 6,345,595 deaths reported globally, with an estimated fatality rate of approximately 1.15% [1]. The severity of COVID-19 can range from asymptomatic infection to life-threatening organ damage. Especially when respiratory failure occurs, the fatality rate of COVID-19 rises sharply [2,3]. Accumulating evidence has suggested that the severity of COVID-19 correlates with a hyper-inflammatory status resembling a cytokine storm [4–6]. Further research has suggested that dysregulation of the immune response, especially T cells, may be significantly involved in the pathological process of COVID-19 [7–9]. Additionally, previous studies have demonstrated that a remarkable reduction in CD8+ T cells could predict mortality in COVID-19 patients [10,11]. However, as one of the essential immunomodulators, corticosteroids have demonstrated efficiency in...
reducing mortality and shorting clinical courses in severe and critically ill patients [12–16], and have been one of the treatments for COVID-19 since the RECOVERY trial confirmed its benefits on 28-day mortality among patients who need respiratory support [17]. Recently, research has suggested that inhaled corticosteroids (ICS) could reduce the probability of needing urgent medical care and enhance clinical recovery in mild patients [18–21]. However, there remains a lack of evidence to determine the effects of corticosteroid treatment on moderate COVID-19 patients.

This study therefore aimed to investigate the effects of methylprednisolone on in-hospital mortality, viral clearance, and length of hospital stay in patients with moderate COVID-19.

2. Materials and methods

2.1. Study design and participants

This retrospective, observational study was conducted on patients diagnosed with COVID-19 pneumonia admitted to Wuhan Huoshenshan Hospital and Wuhan Guanggu Hospital between February 03 and March 30, 2020. All patients were considered for study entry if they were aged ≥18 years and had been diagnosed with moderate SARS-CoV-2 infection. Exclusion criteria were: 1) inability to determine the onset time of the illness; 2) inability to determine the viral clearance time; 3) death or discharge within the first 72h of admission; 4) lacking laboratory test results in the first 72 hours of admission; 5) patients who did not meet either outcome of death or discharge by March 30, 2020. According to the Chinese management guidelines for COVID-19 (version 5.0) [22], SARS-CoV-2 infection is defined as a positive result of real-time reverse transcription-polymerase chain reaction (RT-PCR) tests of nasal and pharyngeal swabs or lower respiratory tract aspirates, or the presence of typical imaging characteristics on chest computed tomography (CT) when laboratory test results are inconclusive. In practical terms, most of the specimens in this study were diagnosed via throat swab.

This study was approved by the Research Ethics Commission of both centers. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used for reporting this study [23].

2.2. Data collection

The epidemiological and demographic data as well as comorbidities, laboratory test results, treatments, outcomes, and vital clinical time points were extracted from electronic medical records and recorded using a standardized data collection form. The comorbidities records included hypertension, diabetes, coronary heart disease, cerebrovascular disease, respiratory disease, liver disease, kidney disease, and cancer. Laboratory test results included lymphocyte count, D-dimer, and lactic dehydrogenase (LDH). Treatments included antiviral therapy (including umifenovir, oseltamivir–ribavirin, hydroxychloroquine, chloroquine phosphate, lopinavir, and ritonavir), antibacterial therapy (including moxifloxacin hydrochloride, levofloxacin, meropenem, azithromycin, cefdinir, cefaclor, ceftriaxone, cefoperazone sulbactam, linezolid, fluconazole, voriconazole, caspofungin, and metronidazole), immunoglobulin therapy, anticoagulation therapy, and methylprednisolone therapy (with data including total dosage and duration). The vital clinical time points included illness onset time, admission time, viral clearance time, and time of discharge or death. Viral clearance time was defined as the time of the first of 2 consecutive negative SARS-CoV-2 RNA tests at least 24h apart. The discharge criteria were the clinical symptoms and signs of COVID-19 having improved or alleviated (body temperature within the normal range for 3 consecutive days, respiratory symptoms improved significantly, and CT images showing apparent absorption of bilateral extensive ground-glass opacification and/or consolidation), and no need for additional or alternative treatments.

2.3. Outcomes

The primary outcome was in-hospital death. The secondary outcomes were 2 disease courses: time from admission to viral clearance, and length of hospital stay.

2.4. Statistical analysis

Continuous variables are presented as means ± SD for normally distributed data and medians and interquartile ranges (IQR) for non-normally distributed data. Categorical variables are summarized as numbers and frequencies with corresponding percentages (N, %). Comparisons used the chi-square tests for categorical variables and Student’s t-test or Mann–Whitney U test for continuous variables. Univariate and multivariate logistic regression were used to explore the risk factors for in-hospital death. Univariate and multivariate linear regression were used to explore the risk factors for different clinical courses. The effect of methylprednisolone on different clinical courses was evaluated using the Kaplan–Meier approach with the log-rank test. The propensity score matching (PSM) method was used to minimize any bias resulting from confounding factors, assuming an imbalance in patient background between the methylprednisolone and non-methylprednisolone groups. Parameters included in the PSM were patient sex, age, number of comorbidities, length from illness onset to admission, lymphocyte count, D-dimer, and LDH because they were considered clinically significant and partly reflected
the prognosis [3,24,25]. The PSM involved 1:1 matching, using the nearest neighbor method with the caliper width set at 0.2.

A p-value <0.05 was considered statistically significant. Statistical analysis was done using SPSS (version 25.0; IBM, Chicago, IL) and R software (version 4.1.0, R Foundation, Vienna, Austria).

3. Results

3.1. Patient characteristics

Of the 4827 total patients diagnosed with COVID-19 at the 2 study centers, 1320 patients met all inclusion and exclusion criteria and were enrolled. The detailed filtering process is shown in Fig. 1.

As shown in Table 1, the median age of 1320 patients was 58.00 (48.00–66.00) years, 656 patients (49.70%) were males, and the median length from illness onset to admission was 22.44 (13.67–30.69) days. A total of 100 (7.6%) patients received methylprednisolone treatment, and 1220 were in the non-methylprednisolone group. In the methylprednisolone group, the median daily dosage and accumulated dosage of methylprednisolone treatment were 41.82 (40.00–61.43) mg/d and 240.00 (120.00–455.00) mg, with a median duration of 4.50 (3.00–7.00) days. There were significant differences in age, number of comorbidities, the length from illness onset to admission, lymphocyte count, D-dimer, and LDH levels between the 2 groups (all p < 0.05).

3.2. Methylprednisolone therapy was not a risk factor for in-hospital death

Overall in-hospital mortality was 0.91% (12/1320), and all 12 patients who finally died were in the methylprednisolone group (Table 1). The median survival time of those 12 patients was 17.72 (11.87–40.61) days. There were significant differences in mortality between the methylprednisolone group and the non-methylprednisolone group before and after PSM (p = 0.000 and p = 0.023). Table 2 shows the results of the univariate and multivariate logistic analysis of risk factors for in-hospital death between the 2 groups before and after PSM. Among all 1320 patients, methylprednisolone therapy was not associated with in-hospital death before PSM (p = 0.908). The LDH (OR = 1.017 [1.003–1.031], p = 0.017), anticoagulation therapy (OR = 101.591 [5.290–1950.878], p = 0.002), and immunoglobulin therapy (OR = 20.748 [1.307–329.267], p = 0.032) were risk factors for in-hospital death (Table 2). After removing the influence of confounding factors by PSM, 90 patients in the methylprednisolone group and 90 patients in the non-methylprednisolone group were analyzed for the primary outcome. Of these 180 patients, all 5 (2.8%) patients who died were in the methylprednisolone group (Table 1). The median survival time of these 5 patients was 19.74 (13.71–40.85) days. In the 90 patients in the methylprednisolone group after PSM, the median daily dosage and accumulated dosage of methylprednisolone treatment were 40.00 (40.00–60.00) mg/d and 200.00 (120.00–380.00) mg, with a median duration of 4.00
3.3. Methylprednisolone therapy was associated with longer time from admission to viral clearance and longer hospital stay

We further assessed the effects of methylprednisolone on different clinical courses in 1308 patients who were cured and discharged, of whom 88 were in the methylprednisolone group and 1220 were in the non-methylprednisolone group. The baseline characteristics of these groups are presented in Table 3.

Before being matched by PSM, age, the length from illness onset to admission, the lymphocyte count, D-Dimer, and LDH levels differed significantly between the 2 groups (all \( p < 0.05 \)), and time from admission to viral clearance and duration of hospital stay also had significant differences between the 2 groups (all \( p < 0.001 \)).

In the 88 patients in the methylprednisolone group before PSM, the median daily dosage and accumulated dosage of methylprednisolone treatment were 40.00 (40.00–60.00) mg/d and 240.00 (120.00–400.00) mg, with a median duration of 4.00 (3.00–7.00) days. Univariate and multivariate linear analysis were used to explore the risk factors for clinical courses between the 2 groups. As shown in Figure 2C, lymphocyte count (OR=−0.084 [−1.372–0.347], \( p<0.001 \)), LDH (OR=0.116 [1.502–3.913], \( p<0.001 \)), methylprednisolone therapy (OR=0.116 [1.502–3.913], \( p<0.001 \)), antiviral therapy (OR = 0.245 [2.270–3.466], \( p<0.001 \)), and antibacterial therapy (OR = 0.145 [1.215–2.590], \( p<0.001 \)) were associated with longer time from admission to viral clearance by multivariate linear analysis. Meanwhile, multivariate linear analysis showed sex (OR = 0.051 [0.049–1.486], \( p = 0.036 \)), age (OR = 0.057 [0.004–0.057], \( p = 0.026 \)), lymphocyte count (OR = −0.124 [−2.303 to −0.976], \( p < 0.001 \)), LDH (OR = 0.142 [0.012–0.26], \( p < 0.001 \)), methylprednisolone therapy (OR = 0.126 [2.281–5.318], \( p < 0.001 \)), antiviral therapy (OR = 0.230 [2.740–4.242], \( p < 0.001 \)), antibacterial therapy (OR = 0.157 [1.810–3.543], \( p < 0.001 \)), and immunoglobulin therapy (OR = 0.065 [0.877–6.032], \( p = 0.009 \)) were associated with longer length of hospital stay (Fig. 2D).

After removing the influence of confounding factors by PSM, 83 patients in the methylprednisolone group and 83 in the non-methylprednisolone group were matched (Table 3). In the 83 patients in the methylprednisolone group after PSM, the median daily dosage and accumulated dosage of methylprednisolone treatment were 40.00 (40.00–60.00) mg/d and 240.00 (120.00–400.00) mg, with a median duration of 4.00 (3.00–7.00) days. After matching by PSM, the time from admission to

---

**Table 1**

The characteristics of patients before and after PSM in multivariate analysis.

| Before PSM | After PSM |
|------------|-----------|
| Gender (M/F) | 594/404 | 594/404 |
| Age (years) | 65.00 (48.00, 71.75) | 64.00 (54.00, 71.75) |
| Number of comorbidities (0/1/2/3/4) | 24.14 (15.97, 30.69) | 26.11 (14.51, 30.71) |
| Admission time to admission (days) | 1.37 (0.92, 1.88) | 1.37 (0.92, 1.88) |
| Laboratory tests: lymphocyte count (10³/L) | 1.08 (0.79, 1.98) | 1.08 (0.79, 1.98) |
| D-Dimer (mg/L) | 1.76 (0.93, 3.00) | 1.76 (0.93, 3.00) |
| LDH (U/mL) | 292.75 (198.60, 392.75) | 292.75 (198.60, 392.75) |
| Dead | 12 (12.00%) | 12 (12.00%) |

**Table 2**

The comparison of patients before and after PSM in multivariate analysis.

| | Before PSM | After PSM |
|---|---|---|
| Methylprednisolone group (n = 1220) | | |
| Gender (M/F) | 594/404 | 594/404 |
| Age (years) | 65.00 (48.00, 71.75) | 64.00 (54.00, 71.75) |
| Number of comorbidities (0/1/2/3/4) | 24.14 (15.97, 30.69) | 26.11 (14.51, 30.71) |
| Admission time to admission (days) | 1.37 (0.92, 1.88) | 1.37 (0.92, 1.88) |
| Laboratory tests: lymphocyte count (10³/L) | 1.08 (0.79, 1.98) | 1.08 (0.79, 1.98) |
| D-Dimer (mg/L) | 1.76 (0.93, 3.00) | 1.76 (0.93, 3.00) |
| LDH (U/mL) | 292.75 (198.60, 392.75) | 292.75 (198.60, 392.75) |
| Dead | 12 (12.00%) | 12 (12.00%) |
viral clearance and hospital stay in the methylprednisolone group were significantly longer than in the non-methylprednisolone group (p < 0.001 and p = 0.006) (Fig. 3A, Fig. 3B). As shown in Figures 3C and 3D, multivariate linear analysis found that LDH (OR = 0.014 [0.002–0.027], p = 0.027), methylprednisolone therapy (OR = 2.172 [0.348–3.995], p = 0.020), and antiviral therapy (OR = 3.657 [1.302–5.303], p = 0.001) were risk factors for longer time from admission to viral clearance. Meantime, methylprednisolone therapy (OR = 3.904 [1.734–6.073], p < 0.001), antiviral therapy (OR = 3.987 [1.653–6.322], p = 0.001), and immunoglobulin therapy (OR = 6.724 [2.530–10.918], p = 0.003) were risk factors for longer length of hospital stay.
4. Discussion

In multiple studies, corticosteroids have shown clinical benefit in reducing mortality and shortening clinical courses in severe and critically ill COVID-19 patients [12–14,17]. In those studies, researchers also found that corticosteroid therapy might have no benefit in patients with mild or moderate COVID-19. Based on those results, the WHO strongly recommended systemic corticosteroid therapy in patients with severe and critically ill COVID-19, but conditionally recommended against using it in non-severe patients [26]. Other research found that ICS may prevent disease progression, reduce the need for urgent medical care, and shorten clinical recovery time in patients with mild disease [18–21]. Hu et al. found that the short-course and low-dose administration of corticosteroids in non-severe patients may reduce the risk of progression to severe COVID-19. However, there were no differences in viral shedding time or length of hospital stay between the corticosteroid and the non-corticosteroid groups [27]. One meta-analysis focused on non-severe COVID-19 patients and found that the corticosteroid group had significantly higher odds of death than did the non-corticosteroids group, with delayed viral clearance and prolonged hospital stay [28]. However, the effects of methylprednisolone on moderate COVID-19 patients, particularly in terms of virus shedding time and hospital stay, remain ambiguous.

The current study showed that methylprednisolone therapy was not associated with in-hospital death of patients with moderate COVID-19 before or after eliminating the influence of confounding factors. These findings align with those of the RECOVERY study, which demonstrated that among 1534 patients with no oxygen requirement, the 28-day mortality in the dexamethasone group was close to that of the non-dexamethasone group [17]. Conclusions from previous studies also support our finding that corticosteroid therapy did not reduce in-hospital mortality [11]. Meta-analyses have demonstrated that corticosteroid therapy is associated with increased mortality in patients with no need for oxygen support [28,29]; however, confounding factors and potential selection bias may limit the application and promotion of these studies. Persistent inflammation in the upper respiratory mucosa has been reported to be potentially highly associated with the progress to severe COVID-19, and ICS have been observed to exhibit significant inflammatory modulatory effects that reduce epithelial damage and improve T-cell response, preventing clinical deterioration [30]. Considering the remarkable efficacy in treating chronic obstructive pulmonary disease and asthma, which are also known to cause lung damage and are strongly related to the immune response, ICS may be a better choice in the early phase of COVID-19 [31].
We also found that methylprednisolone treatment significantly prolonged the hospital stay and time from admission to viral clearance. Those changes may be associated with the suppression of immune cells by the application of methylprednisolone, similar to effects observed in the treatment of severe acute respiratory syndrome and the Middle East respiratory syndrome [32,33]. Previous studies and meta-analyses have also demonstrated that those patients who received corticosteroids were inclined to have delayed viral clearance and more extended hospital stays than were patients with no corticosteroids in moderate COVID-19 [11,27,28,34,35]. However, for some of these results no statistical difference was achieved. Yuan et al. found that corticosteroid therapy was associated with delayed viral clearance and hospital stay but without statistical significance, which may have been because of the shorter duration (median 1.9 days) and lower dosage (median 52.2 mg) of corticosteroids therapy in their study than in ours [35]. Hu et al. found that compared with the non-corticosteroid group, the corticosteroid group had longer hospital stays but no significant differences in viral clearance, possibly because their participants were younger and received lower corticosteroid dosage than in our study [27]. Tang et al. reported delayed viral clearance in the methylprednisolone group compared with the findings in a control group, but there was no difference in hospitalization duration between the 2 groups [11]. In addition, it is worth noting that the lengths from illness onset to admission varied considerably in these studies. Considering that COVID-19 is associated with immune response, which changes as the disease progresses, these 2 clinical courses may have been influenced by different lengths of illness onset to admission, as well as by potential treatments we cannot access.

Our study provides new clues to illustrate the effects of methylprednisolone therapy on moderate COVID-19. Although this exploration of the efficacy of methylprednisolone represents a large sample size from 2 centers, and PSM was used to minimize the confounding biases, this study still has limitations. First, this is an observational study based on medical records, and there may have been some undefined biases that cannot be eliminated. Second, this retrospective analysis did not involve imaging or oxygen support therapy data. Third, some patients in this study may have been treated with therapies such as antipyretics before admission, which would not have been
captured in our dataset. Finally, this study lacked a control group who were treated with other kinds of corticosteroids. A recent study found that methylprednisolone significantly reduced the length of hospital stay (7.4 days vs 10.5 days, p = 0.015) and the need for mechanical ventilation (p = 0.04) compared with dexamethasone [36].

In conclusion, methylprednisolone therapy was not associated with increased in-hospital mortality but with delayed viral clearance and extended hospital stay in moderate COVID-19 patients. In moderate COVID-19, methylprednisolone should be carefully administered considering the disease status and the risk of progression.

Funding
This work was supported by grants from the National Key R&D Program of China (2020YFC0860900) and the Emergency Key Program of Guangzhou Laboratory (EKPG21-30-4).

Author contributions
Xiaoyan Li, Xin Yuan, Zhe Xu, Lei Shi and Lei Huang analyzed and interpreted the patient data and research design; Fu-Sheng Wang and Junliang Fu oversight and leadership responsibility for the research activity planning and execution; Xiaoyan Li and Xin Yuan contributed to writing the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We are grateful to the medical and paramedical staff involved in the care of patients during the study period at Wuhan Huoshenshan Hospital and Wuhan Guanggu Hospital.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data available statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics statement
This study was approved by the Research Ethics Commission of both centers. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used for reporting this study.

Informed consent
Written informed consent was obtained from the patients for publication of this manuscript and any accompanying images.

Reference
[1] WHO Coronavirus (COVID-19), Dashboard (2022) Available from: https://covid19.who.int/. Accessed: July 11.

[2] X Yang, Y Yu, J Xu, et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory med. 8 (5) (2020) 475–481, doi:10.1016/S2213-2600(20)30709-5.

[3] F Zhou, T Yu, R Du, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 395 (10229) (2020) 1054–1062, doi:10.1016/S0140-6736(20)30565-3.

[4] F Coperchini, L Chiavota, L Croce, et al., The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine receptor system. Cytokeiner & growth factor rev. 53 (2020) 25–32, doi:10.1016/j.cytogfr.2020.05.003.

[5] Xiong Y, Liu Y, Cao L, et al., Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections 2020:9(1):761-70. doi:10.1016/j.emico.2020.1747363.

[6] P Mehta, DF McAuley, M Brown, et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet (London, England) 395 (10229) (2020) 1033–1043, doi:10.1016/S0140-6736(20)30628-0.

[7] X. Cao, COVID-19: immunopathology and its implications for therapy, Nature rev. Immunol. 20 (5) (2020) 269–270, doi:10.1038/s41577-020-0508-3.

[8] H Li, L Liu, D Zhang et al., SARS-CoV-2 and viral sepsis: observations and hypotheses, Lancet (London, England) 395 (10225) (2020) 1517–1520, doi:10.1016/S0140-6736(20)30920-x.

[9] C Qin, L Zhou, Z Hu, et al., Dysregulation of immune response in patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: Clin infectious dis: an off. Public. Infect. Dis. Soc. Am. 71 (15) (2020) 752–768, doi:10.1017/cid.2248.

[10] RH Du, LR Liang, CQ Yang, et al., Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study, The European respiratory journal 55 (5) (2020), doi:10.1183/13993003.00524-2020.

[11] X Tang, YM Feng, JX Ni, et al., Early use of corticosteroids may prolong SARS-CoV-2 shedding in non-intensive care patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial, Respiraion 100 (2) (2021) 116–126, doi:10.1159/000512063.

[12] C Wu, X Chen, Y Cai, et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA internal medicine 180 (7) (2020) 934–943, doi:10.1001/jamainternmed.2020.0994.

[13] CMP. Jeronimo, MEL Farias, FFA Val et al., Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metrovict): a randomized, double-blind, Phase IIb, placebo-controlled trial. Clin. Infect. Dis.: an off. Publ. Infect. Dis. Soc. Am. 72 (9) (2021) e737-e881, doi:10.1093/cid/ciaa177.

[14] A Granholm, MW Munch, SN Myatra, et al., Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial, Intensive care med. 48 (1) (2022) 45–55, doi:10.1007/s00134-021-06573-1.

[15] JAC ferne, S Murthy, JV Diaz, et al., Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA 324 (13) (2020) 1320–1341, doi:10.1001/jama.2020.17023.

[16] EJ Cano, X Fonseca Fuentes, C Corsini Campioli, et al., Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis, Chest 159 (3) (2021) 1019–1040, doi:10.1016/j.chest.2020.10.054.

[17] P Horby, WS Lim, JR Emberson, et al., Dexamethasone in hospitalized patients with Covid-19, The New England j. med. 384 (8) (2021) 693–704, doi:10.1056/NEJMc2021436.

[18] S Ramakrishnan, DV Nicolau Jr, B Langford, et al., Inhaled budenoside in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, The Lancet Respiratory medi. 9 (7) (2021) 763–772, doi:10.1016/S2213-2600(21)00160-0.

[19] LM Yu, M Bafadhel, J Dorward, et al., Inhaled budenoside for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet (London, England) 398 (10303) (2021) 843–855, doi:10.1016/S0140-6736(21)00774-4.

[20] A Agusti, F Torres, R. Faner, Early treatment with inhaled budenoside to prevent clinical deterioration in patients with COVID-19, The Lancet Respiratory medi. 9 (7) (2021) 682–683, doi:10.1016/S2213-2600(21)00171-5.

[21] N Ezer, S Belga, O Daneman, et al., Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN NA- pronounced controlled trial, BMJ (Clinical research ed) 375 (2021) e608060, doi:10.1136/bmj-2021-068060.

[22] China NHCostPaRo. Diagnosis and treatment of COVID-19 guideline (fifth version). E. Wu, X. Tian, DG Alman, M Egger, et al., The Strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet (London, England) 370 (9596) (2007) 1453–1457, doi:10.1016/S0140-6736(07)61602-x.
[24] Q Li, Y Cao, L Chen, et al., Hematological features of persons with COVID-19, Leukemia 34 (8) (2020) 2163–2172, doi:10.1038/s41375-020-0910-1.
[25] JJ Zhang, X Dong, YY Cao, et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy 75 (7) (2020) 1730–1741, doi:10.1111/all.14238.
[26] WHO. Therapeutics and COVID-19 Guideline [EB/OL]. 2022-09-16.
[27] Z Hu, Y Lv, C Xu, et al., Clinical use of short-course and low-dose corticosteroids in patients with non-severe COVID-19 during pneumonia progression, Frontiers in public health 8 (2020) 355, doi:10.3389/fpubh.2020.00355.
[28] AK Sahu, R Mathew, R Bhat, et al., Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis, Qjm 114 (7) (2021) 455–463, doi:10.1093/qjmed/hca0212.
[29] L Pasin, P Navalesi, A Zangrillo, et al., Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized controlled trials, J. cardiothoracic and vascular anesthesia 35 (2) (2021) 578–584, doi:10.1053/j.jvca.2020.11.057.
[30] JR Baker, M Mahdi, DV Nicolau Jr, et al., Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis, The Lancet Respiratory medicine 10 (6) (2022) 545–556, doi:10.1016/s2213-2600(22)00062-9.
[31] S Milne, X Li, CX Yang, et al., Inhaled corticosteroids downregulate SARS-CoV-2 related genes in COPD: results from a randomised controlled trial, The Eur. respiratory j. 58 (1) (2021), doi:10.1183/13993003.00130-2021.
[32] N Lee, KC Allen Chan, DS Hui, et al., Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients, J. clin. virol. Offl. Publ. Pan Am. Soc. Clin. Virol. 31 (4) (2004) 304–309, doi:10.1016/j.jcv.2004.07.006.
[33] YM Arabi, Y Mandourah, F Al-Hameed, et al., Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, Am. J. respiratory and critical care med. 197 (6) (2018) 757–767, doi:10.1164/rcrm.201706-1172OC.
[34] J Wang, W Yang, P Chen, et al., The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: a systematic review and meta-analysis, PloS one 16 (4) (2021) e0249481, doi:10.1371/journal.pone.0249481.
[35] M Yuan, X Xu, D Xia, et al., Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis, Shock (Augusta, Ga) 54 (5) (2020) 638–643, doi:10.1097/shk.000000000001574.
[36] K Ranjarb, M Moghadami, A Mirahmadiadeh, et al., Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial, BMC Infect Dis 21 (1) (2021) 337, doi:10.1186/s12879-021-06045-3.